Zydus Lifesciences gets post application action letter for cGMP, PAI at Ahmedabad facility

07 Mar 2024 Evaluate

Zydus Lifesciences has received Post Application Action Letter from the USFDA for the inspection conducted at the Ahmedabad API facility of the company, confirming that the inspected facility has been considered as ready to commercially manufacture and supply the API. 

This facility underwent for-cause cGMP surveillance and Pre-Approval Inspection for manufacturing of drug substances Enzalutamide from December 14 to 22, 2023.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences Share Price

910.00 5.15 (0.57%)
16-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1699.75
Dr. Reddys Lab 1269.30
Cipla 1355.80
Zydus Lifesciences 910.00
Lupin 2220.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×